Blog: Engaging Innovation

October 5, 2018

A Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine

Next-generation sequencing (NGS) is becoming a commonly used tool in cancer treatment. Transparency regarding the clinical performance and utility of different NGS-based tests available will aid in clinical decision-making and facilitate improvements in patient care.  The 7th Annual Blueprint for Breakthrough Forum, held by Friends of Cancer Research (Friends) and Alexandria Real Estate Equities, Inc.,…

Learn More

Ginger Myers* | September 6, 2018

The FDA’s Budget: How Government Funds Safety and Efficacy

The U.S. Food and Drug Administration (FDA) fulfills its mission to protect and advance the public health by overseeing the development and approval of new medical products and ensuring that they are safe and effective for American consumers. When taking into consideration the full range of products the FDA oversees, including not just medical products,…

Learn More

July 25, 2018

The Future Use of Real-World Evidence

  Significant progress has been made in data collection efforts to support use of real-world evidence (RWE) in regulatory settings; however challenges remain, chiefly with combining, organizing, and analyzing data from various information sources. On July 10th, Friends of Cancer Research (Friends) hosted a meeting to present data from a pilot project assessing the use…

Learn More

May 26, 2018

TMB Harmonization Working Group Fall Meeting

Skip to main content Options for the administrative overlayIf you have problems accessing administrative pages on this site, disable the overlay on your profile page.Dismiss this message. Edit Blogs TMB Harmonization Working Group Fall MeetingClose overlayPrimary tabsVIEW EDIT(ACTIVE TAB) REVISIONS NODEQUEUE You are hereHome » TMB Harmonization Working Group Fall Meeting » TMB Harmonization Working…

Learn More

Friends of Cancer Research | April 12, 2018

Safeguarding the Public Health: Enhancing Information About Prescription Drugs

Friends of Cancer Research Congressional Briefing Safeguarding the Public Health: Enhancing Information About Prescription Drugs Patients and their caregivers need access to high quality information about the prescription drugs they use. While many sources of information exist, none can deliver as strong assurances of reliability and scientific rigor as FDA-approved product labels. Labels are the…

Learn More

March 16, 2018

Molecularly Targeted Therapies in Pediatric Cancer

Robust drug development for pediatric cancers is critical to ensuring appropriate access to life-saving drugs and promoting innovation. As such, the FDA Reauthorization Act (FDARA) of 2017 included a provision requiring sponsors to investigate new molecularly targeted cancer drugs and biologics that are determined to be substantially relevant to the growth or progression of pediatric…

Learn More

Jim Omel | January 23, 2018

A Plea to Make Cancer Clinical Trials More Patient Friendly

Jim Omel is a myeloma patient and a cancer research advocate. He spoke at the 2017 Friends of Cancer Research Annual Meeting and was an author of the panel 2 whitepaper, Data Generation to Support Cross-Labeling of Indications for Combination Products. Below are his abridged remarks from the meeting. To view his remarks in full,…

Learn More

Friends of Cancer Research | December 9, 2017

Biopharma Congress III

November 14, 2017 Disruption In Biopharma The Ritz-Carlton, Washington D.C. 1150 22nd Street, NW On Tuesday, November 14, 2017, Friends of Cancer Research (Friends) and Prevision Policy hosted the third annual BioPharma Congress. This year’s event focused on disruption in biopharma and featured speakers such as former FDA Commissioner Dr. Mark McClellan and former Senate…

Learn More

Friends of Cancer Research | December 9, 2017

Friends of Cancer Research Annual Meeting 2017

Panel 1 Whitepaper – Panel 1 Slides Panel 2 Whitepaper – Panel 2 Slides Panel 3 Whitepaper – Panel 3 Slides   This year’s Friends Annual Meeting took place on November 15, 2017. The event began with a keynote by FDA Commissioner Dr. Scott Gottlieb. During his remarks, Dr. Gottlieb reiterated previous commitments for the…

Learn More

Friends of Cancer Research | October 20, 2017

A Blueprint for Breakthrough – Charting the Course for Precision Medicine

Friends of Cancer Research with Alexandria Real Estate Equities, Inc. Co-Host: A Blueprint for Breakthrough – Charting the Course for Precision Medicine Click HERE to access the finalized meeting whitepaper. On Wednesday, September 13, 2017, Friends of Cancer Research (Friends) with Alexandria Real Estate Equities Inc. co-hosted the 6th annual Blueprint for Breakthroughs forum. This…

Learn More